Stockscreener 앱 받기
2.20
2.80%
0.06
시간 외 거래:
2.20
전일 마감가:
$2.14
열려 있는:
$2.11
하루 거래량:
129.58K
Relative Volume:
1.33
시가총액:
$103.69M
수익:
$18.11M
순이익/손실:
$-18.95M
주가수익비율:
-5.0286
EPS:
-0.4375
순현금흐름:
-
1주 성능:
+3.29%
1개월 성능:
+15.84%
6개월 성능:
+7.32%
1년 성능:
-23.08%
1일 변동 폭
$2.11
$2.45
1주일 범위
$2.11
$2.45
52주 변동 폭
$1.325
$3.5807
에이다진 Stock (ADAG) Company Profile
ADAG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
2.20 | 100.86M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
에이다진 Stock (ADAG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | Leerink Partners | Outperform |
| 2025-01-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | 개시 | China Renaissance | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
에이다진 주식(ADAG)의 최신 뉴스
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Adagene’s ADG126 to be Highlighted in Two Presentations at - GlobeNewswire
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - The Manila Times
Adagene Inc. Showcases ADG126 at CSCO Meeting with Promising Results in Advanced MSS Colorectal Cancer - Quiver Quantitative
30% Response Rate: Adagene's Novel Cancer Drug Shows Promise in Hard-to-Treat Colorectal Cancer Trial - Stock Titan
Former YERVOY developer Axel Hoos joins Adagene as advisor - Investing.com
Adagene Inc. Appoints Dr. Axel Hoos as Executive Advisor to Enhance Immuno-Oncology Initiatives - Quiver Quantitative
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - GlobeNewswire
Former $2.5B Scorpion CEO & YERVOY Developer: Adagene's CTLA-4 Platform Could Transform Cancer Care - Stock Titan
Is Adagene Inc. Depositary Receipt’s growth already priced inJuly 2025 Big Picture & Real-Time Buy Zone Alerts - خودرو بانک
Can Adagene Inc. Depositary Receipt maintain sales growthJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - خودرو بانک
What data driven models say about Adagene Inc. Depositary Receipt’s futureWeekly Stock Recap & Weekly High Momentum Picks - Newser
Adagene to Participate in Two Investor Conferences in September - The Manila Times
Biotech Innovator Adagene Scheduled for Major Wall Street Healthcare Conferences in September 2025 - Stock Titan
Adagene to Participate in Investor Conferences in New York in September. - AInvest
Will Adagene Inc. Depositary Receipt see short term momentumTrade Performance Summary & Smart Swing Trading Techniques - Newser
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
What moving averages say about Adagene Inc. Depositary ReceiptWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser
HC Wainwright Issues Pessimistic Forecast for Adagene (NASDAQ:ADAG) Stock Price - Defense World
How to read the order book for Adagene Inc. Depositary Receipt2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser
Q3 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
H.C. Wainwright lowers Adagene stock price target to $7 on development path clarity - Investing.com
Adagene's 22.4% Surge: Clinical Breakthroughs and Strategic Alliances Ignite Biotech Volatility - AInvest
How institutional ownership impacts Adagene Inc. Depositary Receipt stockPortfolio Gains Report & Risk Controlled Daily Plans - Newser
What indicators show strength in Adagene Inc. Depositary ReceiptJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser
Published on: 2025-08-12 20:31:18 - Newser
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Cancer Drug Breakthrough: Adagene's ADG126 Doubles Standard Survival Rate as Sanofi Backs Development - Stock Titan
Is Adagene Inc. Depositary Receipt still worth holding after the dipFree Low Risk Picks for Daily Trading - Newser
Why Adagene Inc. Depositary Receipt is moving todayStock Price Prediction Using AI Tools - Newser
Q2 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
Using R and stats models for Adagene Inc. Depositary Receipt forecastingFree AI Forecast for Trending Stocks - Newser
Adagene (NASDAQ:ADAG) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Leerink Partners Begins Coverage on Adagene (NASDAQ:ADAG) - Defense World
Leerink Partners initiates Adagene stock with Outperform rating on cancer drug potential - Investing.com India
What are analysts’ price targets for Adagene Inc. Depositary Receipt in the next 12 monthsAccelerated investment success - Jammu Links News
Why did ADAG's Q4 2020 EPS miss forecasts drastically? - AInvest
Published on: 2025-07-28 00:29:47 - jammulinksnews.com
Adagene Receives FDA Approval for Phase 2 Trial of Muzastotug in MSS CRC - AInvest
Adagene Announces Regulatory Update on Clinical Development - GlobeNewswire
Adagene (NASDAQ:ADAG) Trading Up 3.8% – Should You Buy? - Defense World
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic By Stocktwits - Investing.com India
Adagene advances muzastotug to phase 2 trial after FDA meeting By Investing.com - Investing.com South Africa
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA - MarketScreener
Adagene Advances Clinical Plan for ADG126 in Colorectal Cancer After FDA Meeting - TipRanks
Adagene advances muzastotug to phase 2 trial after FDA meeting - Investing.com
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewswire
Adagene's Cancer Drug Shows Breakthrough 29% Response Rate, FDA Fast-Tracks Phase 2 Trial - Stock Titan
Adagene Inc. and ConjugateBio Inc. Partner to Develop Novel Antibody Drug Conjugate - MarketScreener
Adagene to provide antibody to ConjugateBio for bispecific ADC development By Investing.com - Investing.com South Africa
Adagene Partners With ConjugateBio to Develop ADC Programs - MarketScreener
에이다진 (ADAG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):